[Ip-health] Drugs watchdog condemns Roche for high price of breast cancer therapy

Elizabeth Rajasingh elizabeth.rajasingh at keionline.org
Fri Aug 8 09:57:19 PDT 2014

An interesting look at the cost of Roche's Kadcyla, in light of the NICE's
decision to decline NHS use.


"The pharmaceuticals giant Roche has been criticised in unprecedented terms
by the government's drugs watchdog for refusing to significantly lower the
price of a breast cancer
<http://www.theguardian.com/society/breast-cancer> drug
whose £90,000-per-patient cost is well over the NHS
<http://www.theguardian.com/society/nhs>'s limit.... Nice decides on
whether medicines are cost-effective for the NHS to buy. The watchdog
cannot approve drugs for use in the NHS that cost more than £30,000 per
patient, but is prepared to raise that ceiling to £50,000 for end-of-life
treatments such as Kadcyla."

another interesting take on the issue:


Elizabeth Rajasingh
Perls Fellow, Knowledge Ecology International
1621 Connecticut Ave. NW, Suite 500
Washington, DC 20009
*elizabeth.rajasingh at keionline.org <elizabeth.rajasingh at keionline.org>* |

More information about the Ip-health mailing list